Highest-materiality recent filing
Korro Bio selects KRRO-111 for AATD; pre-clinical results show >90% RNA editing
KRRO-111 is a GalNAc-conjugated oligonucleotide delivered subcutaneously for AATD.
Korro Bio Q1 net loss narrows to $19.6M; cash at $157M; KRRO-121 filing on track for H2 2026
Net loss of $19.6M vs $23.4M in Q1 2025; R&D spend down to $12.9M from $19.7M.
FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.
Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028
Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.
Cash, equivalents and securities $102.5M at Sept 30, 2025; net loss $18.1M for Q3.
Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025
Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.
Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027
Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.
Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025
Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.
Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025
First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).
Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.
Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).
Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025
Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.
Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets
Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.
Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track
Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.
Korro Bio Chief Scientific Officer Steve Colletti to resign effective August 2, 2024
Steve Colletti, Ph.D., notified Korro Bio of his resignation as Chief Scientific Officer on June 17, 2024.
Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer
Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.
Korro Bio closes $70M private placement to fund Phase 1/2 trial of KRRO-110
Sold 1,249,283 shares at $56.00 per share for gross proceeds of ~$70M.
Korro Bio raises ~$70M in PIPE led by Deep Track Capital; pro-forma cash ~$236M
PIPE of 1,249,283 shares at $56.00 each for gross proceeds of ~$70M.
Korro Bio reports FY 2023 net loss of $81.2M; cash of $166.1M funds operations into 2026
Net loss of $81.2M in 2023 vs. $58.0M in 2022; R&D expenses $57.2M (up from $42.2M).
Frequency closes reverse merger with Korro Bio; combined entity renamed Korro Bio, Inc.
Legacy Korro stockholders own ~91% of combined company; pre-closing financing raised $117.3M at ~$2.78/share.
Frequency Therapeutics terminates ATM equity agreement, transfers Nasdaq listing to Capital Market
Terminated Equity Distribution Agreement with Oppenheimer; only $50,000 in net proceeds raised from 12,767 shares sold.
Terminated Master Lease with LS 75 Hayden LLC effective Jan 31, 2024 (originally through May 31, 2031).
Frequency Therapeutics Q2 net loss narrows to $10.8M; merger with Korro Bio expected Q4 2023
Net loss of $10.8M for Q2 2023, down from $21.3M in Q2 2022 due to hearing program discontinuation.
CSO Christopher Loose resigns; severance includes equity acceleration tied to Korro merger
Christopher Loose resigned as Chief Scientific Officer effective July 28, 2023.
Pre-merger Frequency stockholders expected to own ~8% of combined company; Korro stockholders (incl. new investors) ~92%.
Frequency Therapeutics to merge with Korro Bio in reverse merger; Korro valued at ~$325.6M
Korro Bio equity valued at ~$325.6M; Frequency equity based on net cash at closing.
Frequency Therapeutics cuts workforce by 55%, extends CFO severance terms
Workforce reduction of approximately 55%; severance costs estimated at $1.16M.
Frequency reports Q1 net loss $19.5M; cash $66.7M, debt prepaid; MS program on track for 2024
Net loss of $19.5M vs $23.4M in Q1 2022; R&D expenses $11.4M, G&A $9.2M.
Frequency Therapeutics receives Nasdaq deficiency notice for bid price below $1; CDO departs in RIF
Nasdaq notified FREQ on March 28, 2023 that bid price closed below $1.00 for 30 consecutive business days.
FX-322-208 Phase 2b for hearing loss failed primary endpoint; company ends both FX-322 and FX-345 programs.
Frequency Therapeutics cuts 55% of workforce, appoints interim CEO as Lucchino takes medical leave
Cash, cash equivalents and marketable securities $83.1M as of Dec 31, 2022 (preliminary); $68.9M net of debt.
Frequency Therapeutics completes FX-322 Phase 2b enrollment; Q3 net loss $19.5M, cash $99.3M
Phase 2b study of FX-322 for SNHL enrolled 142 participants; primary endpoint readout expected Q1 2023.
Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.
the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.
Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).
Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.
and Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer
Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer
On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.
and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.
On June 17, 2024, Steve Colletti, Ph.D., notified Korro Bio, Inc. of his intent to resign as its Chief Scientific Officer effective August 2, 2024.
On November 27, 2023, upon the recommendation of its Nominating and Corporate Governance Committee, or the NCG Committee, our Board of Directors, or the Board, appointed Rachel Meyers, Ph.D. as a Class I director, effective November 27, 2023
Nessan Bermingham was appointed Chairperson of the Board.
Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)
Max materiality 1.00 · Median 0.60 · Most common event other_material